/
We are a biopharmaceutical company focused on discovering, developing and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. We have discovered and are developing muscle-directed investigational medicines that may potentially improve the healthspan of people with devastating…
The business is unprofitable at the operating level (-695.44% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 376.6% YoY with margins expanding 2207.3pp.
Negative free cash flow of -$535M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$106M
▲ +376.6% YoY
Net Income (TTM)
-$830M
▼ -33.2% YoY
Op. Margin
-605.06%
▲ +2207.3pp YoY
ROIC
-140.08%
▲ +42.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$549M
▼ -33.8% YoY
Op. Cash Flow (TTM)
-$524M
▼ -28.8% YoY
Net Debt
-$400M
Net Cash Position
Cash & Equiv.
$819M
5Y CAGR: +9.5%
Continue Research